Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Soleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizing the United States market. The drug, Vykat XR, treats a rare genetic disorder. Neurocrine's CEO confirmed the focus remains on the U.S. launch. This move aligns with a trend of delayed European launches amid U.S. pricing policy shifts.

from Markets-Economic Times https://ift.tt/4J7udyV
via